Whitehawk Therapeutics Inc(WHWK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.11 | Insider Own | 42.36% | Shs Outstand | 57.0M | Perf Week | 0.93% |
| Market Cap | 0.18B | Forward P/E | - | EPS next Y | 5.43% | Insider Trans | - | Shs Float | 32.9M | Perf Month | -13.83% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.21 | Inst Own | 57.9% | Short Float | 7.97% | Perf Quarter | -18.18% |
| Income | -0.08B | P/S | - | EPS this Y | -179.22% | Inst Trans | 10.65% | Short Ratio | 7.54 | Perf Half Y | -18.8% |
| Sales | 0.00B | P/B | 1.01 | EPS next 5Y | - | ROA | -42.6% | Short Interest | 2.62M | Perf YTD | 33.88% |
| Book/sh | 3.21 | P/C | 0.97 | EPS past 3/5Y | 50.16% 58.28% | ROE | -44.98% | 52W High | -41.04% ($5.49) | Perf Year | 44% |
| Cash/sh | 3.33 | P/FCF | - | Sales past 3/5Y | -22.27% -13.29% | ROIC | -43.64% | 52W Low | 64.47% ($1.97) | Perf 3Y | -22.3% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1813.57% | Gross Margin | - | Volatility(W/M) | 6.63% 6.22% | Perf 5Y | -88% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.38 | EPS Q/Q | 73.63% | Profit Margin | - | RSI (14) | 42.82 | Recom | 1.57 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.38 | Sales Q/Q | - | SMA20 | -0.96% ($3.27) | Beta | 0.97 | Target Price | $7.33 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -16.06% ($3.86) | Rel Volume | 0.44 | Prev Close | $3.3 |
| Employees | 23 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 32.36% 100% | SMA200 | -15.59% ($3.84) | Avg Volume(3M) | 0.35M | Price | $3.24 |
| IPO | 2017/8/8 | Option/Short | Yes/Yes | Trades | 1071 | Volume | 153,351 | Change | -1.82% |
🧬 A US clinical-stage biotech company developing next-generation antibody-drug conjugate (ADC)-based cancer therapies. Originally known as Adai Biosciences, the company has rebranded to WhiteHawk Therapeutics (WHWK) and is advancing an ADC oncology portfolio targeting high-unmet-need tumors such as lung and gynecological cancers through Phase 1 clinical trials.
Over the past 1 year, roughly in the middle
41% below its 1-year high.
Traded less than usual. That is 44% of its average volume.
WHWK has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -179.2% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -88.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 57.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #308 of 597 in the industry
Based on market cap of $185M.
UPB#306 Upstream Bio Inc $187M PER - 
ZNTL#307 Zentalis Pharmaceuticals Inc $186M PER - WHWK#308 Whitehawk Therapeutics Inc $185M PER - 
BCYC#309 Bicycle Therapeutics Plc ADR $184M PER - 
RNA#310 Atrium Therapeutics Inc $184M PER - 
FAQ
What kind of company is WHWK?
WHWK belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of WHWK?
The market cap of WHWK is approximately $185M, ranking 4,068 within its sector.
What is the 52-week high and low for WHWK?
WHWK has recorded a 52-week high of $5.49 and a low of $1.97.
